ArticleJournal of comparative effectiveness research2025
Healthcare cost comparison between first-line ibrutinib and acalabrutinib in chronic lymphocytic leukemia patients in the Veterans Affairs.
Lindsey Fitzgerald et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.